Quest study shows Haystack MRD test hits 100% specificity in DYNAMIC colorectal cancer specimen cohort

By Public Technologies
  • Quest Diagnostics highlighted a new Journal of Molecular Diagnostics study validating its Haystack MRD blood test in colorectal cancer.
  • Results have already been published, based on retrospective testing of stored samples from the DYNAMIC and DYNAMIC-III clinical trial programs.
  • The study found the test accurately identified patients likely to relapse, with no false alarms reported in the evaluated cohort.
  • Haystack MRD outperformed a commonly used blood biomarker for spotting recurrence, supporting broader clinical adoption and potential treatment-monitoring use.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610010852PR_NEWS_USPR_____NY61005) on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.